Saturated spirocyclics as antiviral agents
AssigneeEnanta Pharmaceuticals, Inc.
InventorsJoseph D. Panarese, Samuel Bartlett, Yat Sun Or
Life of this patent
Estimating the term…
Abstract
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Claims16
A compound represented by Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- A is selected from:
- 1) —R11;
- 2) —OR12;
- 3) —NR17R18;
- and
- 4) —C(R13R14)N(R17R18);
- n is 1, 2, or 3;
- Q1 is selected from:
- 1) —CN;
- 2) —C(O)R15;
- 3) —CH(OH)SO3R16;
- 4) —C(O)NR13R14;
- 5) —C(O)C(O)NR13R14;
- and
- 6) Optionally substituted —C2-C8 alkynyl;
- R1, R2, R3, Q2, and Q3 are each independently selected from:
- 1) Hydrogen;
- 2) Optionally substituted —C1-C8 alkyl;
- 3) Optionally substituted —C2-C8 alkenyl;
- 4) Optionally substituted —C2-C8 alkynyl;
- 5) Optionally substituted —C3-C8 cycloalkyl;
- 6) Optionally substituted 3- to 8-membered heterocycloalkyl;
- 7) Optionally substituted aryl;
- 8) Optionally substituted arylalkyl;
- 9) Optionally substituted heteroaryl;
- and
- 10) Optionally substituted heteroarylalkyl;
- alternatively, R1 and R2 are taken together with the carbon atom to which they are attached to form an optionally substituted 3- to 8-membered carbocyclic ring or an optionally substituted 3- to 8-membered heterocyclic ring;
- alternatively, Q2 and Q3 are taken together with the carbon atom to which they are attached to form an optionally substituted 3- to 8-membered carbocyclic ring or an optionally substituted 3- to 8-membered heterocyclic ring;
- R4 is hydrogen, optionally substituted —C1-C4 alkyl, optionally substituted C2-C4-alkenyl, or optionally substituted —C3-C6 cycloalkyl;
- R11 and R12 are each independently selected from:
- 1) Optionally substituted —C1-C8 alkyl;
- 2) Optionally substituted —C2-C8 alkenyl;
- 3) Optionally substituted —C2-C8 alkynyl;
- 4) Optionally substituted —C3-C8 cycloalkyl;
- 5) Optionally substituted 3- to 8-membered heterocycloalkyl;
- 6) Optionally substituted aryl;
- 7) Optionally substituted arylalkyl;
- 8) Optionally substituted heteroaryl;
- and
- 9) Optionally substituted heteroarylalkyl;
- R13, R14, and R17 each independently selected from:
- 1) Hydrogen;
- 2) Optionally substituted —C1-C8 alkyl;
- 3) Optionally substituted —C2-C8 alkenyl;
- 4) Optionally substituted —C2-C8 alkynyl;
- 5) Optionally substituted —C3-C8 cycloalkyl;
- 6) Optionally substituted 3- to 8-membered heterocycloalkyl;
- 7) Optionally substituted aryl;
- 8) Optionally substituted arylalkyl;
- 9) Optionally substituted heteroaryl;
- and
- 10) Optionally substituted heteroarylalkyl;
- alternatively, R13 and R14 are taken together with the carbon atom to which they are attached to form an optionally substituted 3- to 8-memberedheterocyclic ring;
- R15 is hydrogen, hydroxy, or optionally substituted —C1-C8 alkyl;
- R16 is hydrogen or Na30;
- and
- R18 is selected from:
- —C(O)R11;
- —C(O)OR11;
- —C(O)NR13R14;
- —S(O)2R11;
- Hydrogen;
- Optionally substituted —C1-C8 alkyl;
- Optionally substituted —C2-C8 alkenyl;
- Optionally substituted —C2-C8 alkynyl;
- Optionally substituted —C3-C8 cycloalkyl;
- Optionally substituted 3- to 8-membered heterocycloalkyl;
- Optionally substituted aryl;
- Optionally substituted arylalkyl;
- Optionally substituted heteroaryl;
- and
- Optionally substituted heteroarylalkyl.
Dependencies are inferred from the claim text.